Special Issue "Mucocutaneous Manifestations of HIV after 40 Years from the First Case"

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".

Deadline for manuscript submissions: 31 December 2021.

Special Issue Editors

Prof. Dr. Elena Maria Varoni
E-Mail Website
Guest Editor
Prof. Dr. Giovanni Lodi
E-Mail Website
Co-Guest Editor
Department of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, Milan, Italy
Interests: oral medicine; oral diseases; oral health; evidence based dentistry

Special Issue Information

Dear Colleagues,

The year 1991 represents a crucial year for the human immunodeficiency virus (HIV) and the acquired immunodeficiency syndrome (AIDS) epidemic. In June of that year, the Center for Disease Control (CDC) reported two clusters of rare diseases, Pneumocystis carinii pneumonia and Kaposi’s Sarcoma, respectively, which mostly affected gay American men, previously healthy.

Since then, the scientific community has been tirelessly devoted to investigating etiopathogenesis, diagnosis, prevention and treatment, achieving important successes.

Most patients show at least one mucocutaneous HIV/AIDS-related manifestation in their clinical history; it often occurs at the early onset of the infection and correlates with the immunologic stage and the use of highly active antiretroviral therapy (HAART).

Efforts towards new, additional therapies and preventive strategies are now underway, following the important recent discoveries on AIDS pathogenesis. These therapies have outcomes on oral and cutaneous disorders, emphasizing the need for a multidisciplinary approach to these patients.

We kindly invite clinical and basic researchers to submit original research, review or expert opinion articles about pathogenesis, diagnosis and treatment of HIV/AIDS, with a particular focus on skin and oral disorders.

Prof. Dr. Elena Maria Varoni
Guest Editor
Prof. Dr. Giovanni Lodi
Co-Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • muco-cutaneous diseases
  • oral diseases
  • acquired immunodeficiency
  • HIV vaccine
  • virome
  • Kaposi’s Sarcoma
  • human papillomavirus
  • candidiasis
  • anti-retroviral therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Prevalence and Risk Factors of Infection with High Risk Human Papilloma Viruses among HIV-Positive Women with Clinical Manifestations of Tuberculosis in a Middle-Income Country
Biomedicines 2021, 9(6), 683; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines9060683 - 16 Jun 2021
Viewed by 585
Abstract
Women living with HIV-1 are at high risk of infection with human papillomavirus of high carcinogenic risk (HR HPVs). M. tuberculosis (TB) promotes HPV infection and increases the risk to develop HPV-associated cancer. Our knowledge of persisting HR HPVs genotypes, and of the [...] Read more.
Women living with HIV-1 are at high risk of infection with human papillomavirus of high carcinogenic risk (HR HPVs). M. tuberculosis (TB) promotes HPV infection and increases the risk to develop HPV-associated cancer. Our knowledge of persisting HR HPVs genotypes, and of the factors promoting HR HPV infection in people living with HIV-1 with clinical TB manifestations is sparse. Here, we analyzed 58 women living with HIV-1 with clinical TB manifestations (WLWH with TB) followed up in specialized centers in Russia, a middle income country endemic for HIV-1 and TB, for the presence in cervical smears of DNA of twelve HR HPV genotypes. DNA encoding HPV16 E5, E6/E7 was sequenced. Sociodemographic data of patients was collected by questionnaire. All women were at C2-C3 stages of HIV-infection (by CDC). The majority were over 30 years old, had secondary education, were unemployed, had sexual partners, experienced 2–3 pregnancies and at least one abortion, and were smokers. The most prevalent was HPV16 detected in the cervical smears of 38% of study participants. Altogether 34.5% of study participants were positive for HR HPV types other than HPV16; however, but none of these types was seen in more than 7% of tested samples. Altogether, 20.7% of study participants were positive for several HR HPV types. Infections with HPVs other than HPV16 were common among WLWH with generalized TB receiving combined ART/TB-therapy, and associated with their ability to work, indirectly reflecting both their health and lifestyle. The overall prevalence of HR HPVs was associated with sexual activity of women reflected by the number of pregnancies, and of HPV 16, with young age; none was associated to CD4+-counts, route of HIV-infection, duration of life with HIV, forms of TB-infection, or duration of ART, characterizing the immune status. Thus, WLWH with TB—especially young—were predisposed to infection with HPV16, advancing it as a basis for a therapeutic HPV vaccine. Phylogenetic analysis of HPV16 E5, E6/E7 DNA revealed no common ancestry; sequences were similar to those of the European and American HPV16 strains, indicating that HPV vaccine for WLWH could be the same as HPV16 vaccines developed for the general population. Sociodemographic and health correlates of HR HPV prevalence in WLWH deserve further analysis to develop criteria/recommendations for prophylactic catch-up and therapeutic HPV vaccination of this highly susceptible and vulnerable population group. Full article
Show Figures

Figure 1

Back to TopTop